Abstract
Synopsis
The antiviral nucleoside analogue ganciclovir has demonstrated in vitro activity against human cytomegalovirus and effectively treats infection caused by this organism in various immunocompromised patient groups. The drug prolongs time to progression in patients with acquired immune deficiency syndrome (AIDS)-related cytomegalovirus retinitis although life-long maintenance therapy is required. Direct comparisons between ganciclovir and foscarnet in this indication are few; nevertheless, the 2 drugs appear to have equal therapeutic efficacy in treating cytomegalovirus retinitis although results from 1 study in this indication suggest that foscarnet has an advantage in terms of patient survival. AIDS-related gastrointestinal and, to a lesser extent, pulmonary cytomegalovirus infection also respond to treatment with ganciclovir; maintenance therapy does not appear to be required in these latter 2 indications. Ganciclovir is also useful against cytomegalovirus infection in organ transplant recipients. The drug is most effective when given prophylactically or as early treatment for asymptomatic infection in bone marrow transplant recipients; treatment of established infection is less ef-fective in this patient group. However, established infection in solid organ transplant recipients appears to respond to treatment with ganciclovir.
The most common adverse event during ganciclovir therapy is haematological toxicity but this appears to be readily reversible on discontinuation of the drug. In addition, coadministration of granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage CSF (GM-CSF) has been shown to prevent ganciclovir-associated neutropenia.
Thus, ganciclovir is a valuable treatment for cytomegalovirus infection in patients with AIDS and in organ transplant recipients. Further studies comparing ganciclovir and foscarnet — ideally incorporating the use of G-CSF or GM-CSF to prevent ganciclovir-associated neutropenia and assessing survival as I end-point — should further clarify the relative role of ganciclovir as treatment or prophylaxis for cytomegalovirus infection.
Antiviral Activity
Ganciclovir has demonstrated good in vitro activity against human cytomegalovirus and is considerably more potent than aciclovir (acyclovir) against this or-ganism. The combination of ganciclovir and foscarnet synergistically inhibited replication of human cytomegalovirus in vitro. The presence of ganciclovir reduced the in vitro activity of zidovudine against human immunodeficiency virus in 2 studies but enhanced it in another.
Ganciclovir has demonstrated in vivo efficacy in animal models including disseminated and pulmonary murine cytomegalovirus infection and murine cyto-megalovirus encephalitis.
Cytomegalovirus strains resistant to ganciclovir appear to have point mutations in a gene encoding a kinase that phosphorylates ganciclovir and another encoding a viral DNA polymerase. The true incidence of resistance to ganciclovir is still unclear; however, the clinical impact of resistance has been minimal to date.
Pharmacokinetic Properties
Intravenous administration of 1 to 5 mg/kg doses of ganciclovir produces linearly increasing peak plasma concentrations; no evidence of accumulation has been observed in patients with normal renal function. Intravitreal administration of ganciclovir produces high concentrations in vitreal fluid with minimal, if any, systemic absorption.
The bioavailability of orally administered ganciclovir was approximately 6% after administration of 10 mg/kg, or 1000mg doses.
Concentrations of ganciclovir in cerebrospinal fluid were lower than those reported in serum after intravenous administration. Ganciclovir has a steady-state volume of distribution of approximately 32 to 44.5 L/1.73m2. Almost 100% of an intravenously administered dose of ganciclovir is excreted in the urine of patients with normal renal function. The drug has an elimination half-life of between 2 and 4 hours after intravenous administration of 1 to 5 mg/kg doses. Clearance decreases linearly with decreasing creatinine clearance in patients with renal dysfunction. Ganciclovir is effectively cleared by haemodialysis.
Therapeutic Use
Symptomatic cytomegalovirus infection occurs predominantly in immunocompromised patients; thus, most studies evaluating the efficacy of ganciclovir against cytomegalovirus infection have been conducted in this patient group. Many noncomparative trials suggest that intravenous ganciclovir is an effective treatment for acquired immune deficiency syndrome (AIDS)-related cytomegalovirus retinitis. Rapid progression of retinitis has been observed when ganciclovir therapy is deferred in patients whose retinitis is not an immediate threat to sight. Combination therapy with ganciclovir and either foscarnet or (to a lesser extent) cytomegalovirus immune globulin appears to be effective, especially in patients refractory to ganciclovir monotherapy.
Few direct comparisons of ganciclovir and foscarnet have been conducted. Although the 2 drugs appear to be similar in terms of efficacy against cytomegalovirus retinitis, the Studies of Ocular Complications of AIDS (SOCA) research group and AIDS clinical trials group (ACTG) trial revealed a survival advantage in foscarnet versus ganciclovir recipients in this indication.
Intravitreal injection of ganciclovir has been shown to be as effective as intravenous administration for treatment of AIDS-related cytomegalovirus retinitis and has proven useful in patients unable to tolerate systemic administration. Preliminary studies of sustained-release intraocular formulations designed to improve patient acceptability have provided favourable results as have trials evaluating the use of oral ganciclovir maintenance therapy in patients with cytomegalovirus retinitis.
Limited data suggest that ganciclovir may be an effective treatment for AIDS-related gastrointestinal cytomegalovirus infection and, to a lesser extent, AIDS-related cytomegalovirus pneumonia.
A number of studies have shown ganciclovir to be a useful treatment for established cytomegalovirus infection in adult organ transplant recipients. Results from a small number of studies in paediatric transplant recipients are also favourable. The drug has been studied as prophylaxis, early treatment of asymptomatic infection and treatment for established symptomatic infection. Although more studies are required to confirm initial findings, it appears that bone marrow transplant recipients benefit most from prophylaxis or early treatment; results from studies evaluating the treatment of established cytomegalovirus infection in this patient group are less favourable. However, treatment of established infection is effective in solid organ transplant recipients.
Results from a single pilot study suggest that 3 months’ maintenance therapy with ganciclovir after 2 weeks’ induction therapy improves outcome in infants with congenital cytomegalovirus infection compared with 2 weeks’ therapy alone.
Tolerability
Neutropenia and thrombocytopenia are the most common adverse events in patients receiving ganciclovir, occurring, respectively, in 38 and 20% of patients who received ganciclovir during the compassionate use programme. Haematological adverse events during ganciclovir therapy are usually reversible on withdrawal of the drug. Preliminary studies suggest that concomitant administration of granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage CSF (GM-CSF) can prevent ganciclovir-associated neutropenia and confirmatory results are awaited with interest. Less common adverse events reported during ganciclovir therapy include central nervous system symptoms, abnormal liver function values, fever and rash.
Drug Interactions
The toxicity profiles of ganciclovir and zidovudine overlap and reduction of the zidovudine dosage is sometimes required in patients receiving the 2 drugs concomitantly. Concurrent administration of ganciclovir with other drugs that inhibit replication in rapidly dividing cell populations is not recommended.
Dosage and Administration
The recommended dosage regimen for ganciclovir as treatment for patients with cytomegalovirus retinitis and normal renal function is 5 mg/kg (as a constant intravenous infusion over 1 hour) every 12 hours for 14 to 21 days. If required, maintenance doses of 5 mg/kg/day (as a constant intravenous infusion over 1 hour) 7 days/week, or 6 mg/kg/day (similarly administered) 5 days/week, can be given following the initial induction regimen. The same dosages with a shorter (7 to 14 days) induction regimen are recommended for the prevention of cytomegalovirus disease in transplant recipients. The drug should be infused over a 1-hour period. Subcutaneous or intramuscular administration is not recommended.
Dosage reductions according to creatinine clearance are recommended in patients with renal impairment.
Intravitreal ganciclovir is generally given at a dose of 200 to 400μg once or twice weekly during induction therapy, weekly maintenance doses are then given.
Extreme caution is warranted before ganciclovir is used in children, because the safety of the drug in this population has not been established.
Article PDF
Similar content being viewed by others
References
Faulds D, Heel RC. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs 1990; 39: 597–638
Andrei G, Snoeck R, Schols D, et al. Comparative activity of selected antiviral compounds against clinical isolates of human cytomegalovirus. Eur J Clin Microbiol Infect Dis 1991; 10: 1026–33
Biron KK, Stanat SC, Sorrell JB, et al. Metabolic activation of the nucleoside analog 9-[-hydroxy-1-(hydroxymethyl)-ethoxy]methylguanine in human diploid fibroblasts infected with human cytomegalovirus. Proc Natl Acad Sci USA 1985; 82: 2473–7
Biron KK, Fyfe JA, Stanat SC, et al. A human cytomegalovirus mutant resistant to the nucleoside analog 9-[-hydroxy-1-(hydroxymethyl)ethoxy]methylguanine (BW B759U) induces reduced levels of BW B759U triphosphate. Proc Natl Acad Sci USA 1986; 83: 8769–73
Cole NL, Balfour Jr HH. In vitro susceptibility of cytomegalovirus isolates from immunocompromised patients to acyclovir and ganciclovir. Diagn Microbiol Infect Dis 1987; 6: 255–61
Duke AE, Smee DF, Chernow M, et al. In vitro and in vivo activities of phosphate derivatives of 9-(1,3-dihydroxy-2-pro-poxymethyl)-guanine against cytomegaloviruses. Antiviral Res 1986; 6: 299–308
Konno K, Yokota T, Baba M, et al. Susceptibility of HCMV clinical isolates to ganciclovir and HPMPC. Antiviral Res 1993; 20 Suppl.1: 111
Rush J, Mills J. Effect of combinations of difluoromethylornithine (DFMO) and 9[1,3-dihydroxy-2-propoxy)methyl]guanine (DHPG) on human cytomegalovirus. J Med Virol 1987; 21: 269–76
Shigeta S, Konno K, Baba M, et al. Comparative inhibitory effects of nucleoside analogues on different clinical isolates of human cytomegalovirus in vitro. J Infect Dis 1991; 163: 270–5
Smee DF, Martin JC, Verheyden JPH, et al. Anti-herpesvirus activity of the acyclic nucleoside 9-(1,3-dihydroxy-2-pro-poxymethyl)guanine. Antimicrob Agents Chemother 1983; 23: 676–82
Snoeck R, Schols D, Andrei G, et al. Antiviral activity of antocytomegalovirus agents (HPMPC, HPMPA) assessed by a flow cytometric method and DNA hybridization technique. Antiviral Res 1991; 16: 1–9
Stals FS, De Clercq E, Bruggeman CA. Comparative activity of (S)-1 -(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine against rat cytomegalovirus infection in vitro and in vivo. Antimicrob Agents Chemother 1991; 35: 2262–6
Taylor DL, Jeffries DJ, Taylor-Robinson D, et al. The susceptibility of adenovirus infection to the anti-cytomegalovirus drug, ganciclovir (DHPG). FEMS Microbiol Lett 1988; 49: 337–41
Tolman RL, Field AK, Karkas JD, et al. 2’-nor-cGMP: a secocyclic nucleotide with powerful anti-DNA-viral activity. Biochem Biophys Res Commun 1985; 128: 1329-35
Bakker-Woudenberg IAJM, Lokerse AJ, Ten Kate M. Increased efficacy of ganciclovir and foscarnet inhibition of cytomegalovirus replication in vitro by encapsulation in liposomes. Scand J Infect Dis 1991; 23 Suppl. 74: 54–7
Snoeck R, Andrei G, Schols D. Activity of different antiviral drug combinations against human cytomegalovirus replication in vitro. Eur J Clin Microbiol Infect Dis 1992; 11: 1144–55
Manischewitz JF, Quinnan Jr GV, Lane HC, et al. Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro. Antimicrob Agents Chemother 1990; 34: 373–5
Hamzeh FM, Spector T, Lietman PS. 2-acetylpyridine 5-[(di-methylamino)thiocarbonyl]-thiocarbonohydrazone (1110U81) potently inhibits human cytomegalovirus replication and potentiates the antiviral effects of ganciclovir. Antimicrob Agents Chemother 1993; 37: 602–4
Nokta M, Tolpin M, Nadler P. Combination effects of a human monoclonal anti cytomegalovirus (CMV) antibody (MSL 109) and foscarnet or ganciclovir on CMV replication in vitro. Antiviral Res 1993; 20 Suppl.1: 110
Feng JS, Crouch JY, Tian PY, et al. Zidovudine antagonizes the antiviral effects of ganciclovir against cytomegalovirus infection in cultured cells and in guinea pigs. Antiviral Chem Chemother 1993; 4: 19–25
Medina DJ, Hsiung GD, Mellors JW. Ganciclovir antagonizes the anti-human immunodeficiency virus type 1 activity of zidovudine and didanosine in vitro. Antimicrob Agents Chemother 1992; 36: 1127–30
Cox S, Vissgården A, Wahren B. Effect upon the anti-HIV activity of 3’-azido-3’-deoxythymidine and 3’-fluoro-3’-deoxythymidine of combination with anti-herpes nucleoside analogues. Antiviral Chem Chemother 1993; 4: 41–7
Gowland PL, Küster H, Nadai V, et al. Ganciclovir reduces the amount of intracellular zidovudine phosphorylation products [abstract no. PO-B31-2218]. 9th International Conference on AIDS; 1993, Jun 6–11; Berlin, 505
Freitas VR, Fraser-Smith EB, Chiu S. Efficacy of ganciclovir in combination with zidovudine against cytomegalovirus in vitro and in vivo. Antiviral Res 1993; 21: 301–15
Mocarski ES, Bonyhadi M, Salimi S, et al. Human cytomegalovirus in a SCID-hu mouse: thymic epithelial cells are prominent targets of viral replication. Proc Natl Acad Sci USA 1993; 90: 104–8
Banister S, Pomeroy C. Effect of ganciclovir on cytomegalovirus(CMV)-associated immunosuppression: studies in a mouse model of murine CMV-induced reactivation of T. Gondii pneumonia. Clin Res 1992; 40: 717A
Cheng Y-C, Huang E-S, Lin J-C, et al. Unique spectrum of activity of 9-[(1,3-dihydroxy-2-propoxy)methyl]-guanine against herpesviruses in vitro and its mode of action against herpes simplex virus type 1. Proc Natl Acad Sci USA 1983; 80: 2767–70
Field AK, Davies ME, DeWitt C, et al. 9-[2-hydroxy-1-(hydroxymethyl)ethoxy]methylguanine: a selective inhibitor of herpes group virus replication. Proc Natl Acad Sci USA 1983; 80: 4139–43
Jacobson MA, Odonnell JJ. Approaches to the treatment of cytomegalovirus retinitis — ganciclovir and foscarnet. J Acquir Immune Defic Syndr 1991; 4 Suppl. 1: 11–5
Smee DF, Boehme R, Chernow M, et al. Intracellular metabolism and enzymatic phosphorylation of 9-(1,3-dihyhdroxy-2-propoxymethyl)guanine and acyclovir in herpes simplex virus-infected and uninfected cells. Biochem Pharmacol 1985; 34: 1049–56
Smee DF. Interaction of 9-(1,3-dihydroxy-2-propoxymethyl)-guanine with cytosol and mitochondrial deoxyguanosine kinases: possible role in anti-cytomegalovirus activity. Mol Cell Biochem 1985; 69: 75–81
Meijer H, Bruggerman CA, Dormans PHJ, et al. Human cytomegalovirus induces a cellular deoxyguanosine kinase, also interacting with acyclovir. FEMS Microbiol Lett 1984; 25: 283–7
Littler E, Stuart AD, Chee MS. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral analogue ganciclovir. Nature 1992; 358: 160–2
Sullivan V, Talarico CL, Stanat SC, et al. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 1992; 358: 162–4
Boehme RE. Phosphorylation of the antiviral precursor 9-(1,3-dihydroxy-2-propoxymethyl)guanine monophosphate by guanylate kinase isozymes. J Biol Chem 1984; 259: 12346–9
Matthews T, Boehme R. Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis 1988; 10: 490–4
Mar E-C, Cheng Y-C, Huang E-S. Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitro. Antimicrob Agents Chemother 1983; 24: 518–21
Erice A, Chou S, Biron KK, et al. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med 1989; 320: 289–93
Drew WL, Miner RC, Busch DF, et al. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis 1991; 163: 716–9
Leport C, Puget S, Pepin JM, et al. Cytomegalovirus resistant to foscarnet: clinicovirologic correlation in a patient with human immunodeficiency virus. J Infect Dis 1993; 168: 1329–30
Stanat SC, Reardon JE, Erice A, et al. Ganciclovir-resistant Cytomegalovirus clinical isolates: mode of resistance to ganciclovir. Antimicrob Agents Chemother 1991; 35: 2191–7
Lurain NS, Thompson KD, Holmes EW, et al. Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents. J Virol 1992; 66: 7146–52
Dworkin RJ, Miner RC, Drew WL. In vitro exposure of cytomegalovirus-infected cells to high concentrations of acyclovir induces resistance to ganciclovir. Antiviral Res 1991; 15 Suppl.1: 108
Campos F, Pou L, Pascual C. Serum monitoring of ganciclovir. Ther Drug Monit 1993; 15: 156
De Miranda P, Burnette T, Cederberg D, et al. Absorption and pharmacokinetics of the antiviral 9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]guanine (BW b759U) in humans. Abstracts of the 1986 ICAAC 200 1986
Jacobson MA, De Miranda P, Cederberg DM, et al. Human pharmacokinetics and tolerance of oral ganciclovir. Antimicrob Agents Chemother 1987; 31: 1251–4
Follansbee S, Busch D, Connor J, et al. Phase I study of the safety and pharmacokinetics of oral ganciclovir [abstract no. F.B.9.1]. Proceedings of the Sixth International Conference on AIDS; 1990; San Francisco.
Byrne AK, Lavelle J, Follensbee S, et al. Multiple dose crossover pharmacokinetic study to evaluate the effect of food on the relative bioavailability of oral ganciclovir [abstract no. PuB 7077]. Proceedings of the VIII International Conference on AIDS and the III STD World Congress; 1992 Jul 19–24; Amsterdam, 62
Henry K, Cantrill H, Fletcher C, et al. Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS. Am J Ophthalmol 1987; 103: 17–23
Ashton P, Brown JD, Pearson PA, et al. Intravitreal ganciclovir pharmacokinetics in rabbits and man. J Ocul Pharmacol 1992; 8: 343–7
Shepp DH, Dandliker PS, de Miranda P, et al. Activity of 9-2-hydroxy-1-(hydroxymethyl)ethoxymethyl guanine in the treatment of cytomegalovirus pneumonia. Ann Intern Med 1985; 103: 368–73
Fletcher C, Sawchuk R, Chinnock B, et al. Human pharmacokinetics of the antiviral drug DHPG. Clin Pharmacol Ther 1986; 1: 281–6
Laskin DL, Stahl-Bayliss CM, Kaiman CM, et al. Use of ganciclovir to treat serious cytomegalovirus infections in patients with AIDS. J Infect Dis 1987; 155: 323–7
Jabs DA, Wingard JR, de Bustros S, et al. BW B759U for cytomegalovirus retintis: intraocular drug penetration [letter]. Arch Ophthalmol 1986; 104: 1436–7
Jabs DA, Newman C, De Bustros S, et al. Human pharmacokinetics and tolerance of oral ganciclovir. Antimicrob Agents Chemother 1987; 31: 1251–4
Kuppermann BD, Quiceno JI, Flores-Aguilar M, et al. Intravitreal ganciclovir concentration after intravenous administration in AIDS patients with cytomegalovirus retinitis: implications for therapy. J Infect Dis 1993; 168: 1506–9
Henderson Gl, Hu ZQ, Yang Y, et al. Ganciclovir transfer by human placenta and its effects on rat fetal cells. Am J Med Sci 1993; 306: 151–6
Henry K, Cantrill H, Fletcher C, et al. Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS. Am J Ophthalmol 1987; 103: 17–23
Harbison MA, De Girolami PC, Jenkins RL, et al. Ganciclovir therapy of severe cytomegalovirus infections in solid-organ transplant recipients. Transplantation 1988; 46: 82–8
Weiler S, Liao SHT, Cederberg DM, et al. The pharmacokinetics of ganciclovir in patients with cytomegalovirus (CMV) infections. J Pharm Sci 1987; 76: S120
Lake KD, Fletcher CV, Love KR, et al. Ganciclovir pharmacokinetics during renal impairment. Antimicrob Agents Chemother 1988; 32: 1899–900
Boulieu R, Bastien O, Bleyzac N. Pharmacokinetics of ganciclovir in heart transplant patients undergoing continuous venovenous hemodialysis. Ther Drug Monit 1993; 15: 105–7
Trang JM, Kidd L, Gruber W, et al. Linear single-dose pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. Clin Pharmacol Ther 1993; 53: 15–21
Jacqz-Aigrain E, Macher MA, Sauvageonmarthe H, et al. Pharmacokinetics of ganciclovir in renal transplant children. Pediatr Nephrol 1992; 6: 194–6
Drew WL. Cytomegalovirus infection in patients with AIDS. Clin Infect Dis 1992; 14: 608–15
Ho M. Cytomegalovirus. In: Mandell GL, Douglas RG, Bennett JE, editors. Principles and Practice of Infectious Diseases. 3rd ed. New York: Churchill Livingstone, 1990: 1159-72
Luckie A, Ai E. Diagnosis and management of cytomegalovirus retinitis in AIDS. Curr Opin Ophthalmol 1993; 4: 81–9
Polis MA. Foscarnet and ganciclovir in the treatment of cytomegalovirus retinitis. J Acquir Immune Defic Syndr 1992; 5 Suppl. 1: 3–10
Adan DA, Gattell JM, Cabot J, et al. Tratamiento con ganciclovir de la retinitis por citomegalovirus en pacientes afectos de sida. Arch Soc Esp Oftal 1990; 58: 475–8
Buhles WC, Mastre Jr BJ, Tinker AJ. Ganciclovir treatment of life- or sight-threatening cytomegalovirus infection: experience in 314 immunocompromised patients. Rev Infect Dis 1988; 10 (3 Suppl.): S495-506
D’Antonio D, Iacone A, Fioritoni G, et al. Patterns of cytomegalovirus retinitis in immunocompromised patients treated with 9-(2-hydroxy-1-(hydroxymethyl)ethoxymethyl)guanine (ganciclovir). J Chemother 1991; 3: 162–6
Heinemann M-H. Long-term intravitreal ganciclovir therapy for cytomegalovirus retinopathy. Arch Ophthalmol 1989; 107: 1767–72
Millar AB, Miller RF, Patou G, et al. Treatment of cytomegalovirus retinitis with zidovudine and ganciclovir in patients with AIDS: outcome and toxicity. Genitourin Med 1990; 66: 156–8
Wolitz R. Intravitreal ganciclovir in patients with progressive retinitis [abstract no. PO-B16-736]. 9th International Conference on AIDS; 1993 Jun 6–11; Berlin 424.
Jacobson MA, O’Donnell JJ, Porteous D, et al. Retinal and gastrointestinal disease due to cytomegalovirus in patients with the acquired immune deficiency syndrome: prevalence, natural history, and response to ganciclovir therapy. Q J Med 1988; 254: 473–86
Jacobson MA, O’Donnell JJ, Brodie HR, et al. Randomized prospective trial of ganciclovir maintenance therapy for cytomegalovirus retinitis. J Med Virol 1988; 25: 339–49
Laskin OL, Cederberg DM, Mills J, et al. Ganciclovir for the treatment and suppression of serious infections caused by cytomegalovirus. Am J Med 1987; 83: 201–7
Feinberg J, Katz D, Mastre B, et al. Ganciclovir (GCV) in AIDS patients with immediately sight-threatening CMV retinitis (ISTCR): initial summary of ‘treatment IND’ data [abstract no. Th.B.432]. Proceedings of the 6th International Confer-ence on AIDS; 1990 Jun 20–24; San Francisco, 230.
McCluskey P, Wakefield D, Morgan M. Cytomegalovirus retinopathy and the acquired immune deficiency syndrome: results of treatment with ganciclovir. Aust NZ J Ophthalmol 1990; 18: 385–91
Spector SA, Weingeist T, Pollard RB, et al. A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. J Infect Dis 1993; 168: 557–63
Jordan WC. Use of gancyclovir in AIDS patients with low CD4 counts and high IgG titers as preventive therapy against CMV infection. J Natl Med Assoc 1991; 83: 755–68
Jacobson MA, O’Donnell JJ, Rousell R, et al. Failure of adjunctive cytomegalovirus intravenous immune globulin to improve efficacy of ganciclovir in patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis: a phase 1 study. Antimicrob Agents Chemother 1990; 34: 176–8
Giimbel H, Dardenne C, Stark T, et al. A clinical study of ganciclovir versus combined ganciclovir and CMV hyperimmune globulin in the treatment of CMV-retinitis in AIDS patients [abstract no. 250-6]. Invest Ophthalmol Vis Sci 1992; 33: 742
Wilde MI, Langtry HD. Zidovudine: an update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1993; 46: 515–78
Hochster H, Dieterich D, Bozzette S, et al. Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS. An AIDS Clinical Trials Group Study. Ann Intern Med 1990; 113: 111–7
Nelson MR, Barter G, Hawkins D, et al. Simultaneous treatment of cytomegalovirus retinitis with ganciclovir and foscarnet. Lancet 1991; 338: 250
Coker RJ, Tomlinson D, Horner P, et al. Treatment of cytomegalovirus retinitis with ganciclovir and foscarnet. Lancet 1991; 338: 574–5
Enting R, de Gans J, Reiss P, et al. Ganciclovir/foscarnet for cytomegalovirus meningoencephalitis in AIDS. Lancet 1992; 340: 559–60
Butler KM, De Smet MD, Husson RN, et al. Treatment of aggressive cytomegalovirus retinitis with ganciclovir in combination with foscarnet in a child infected with human immunodeficiency virus. J Pediatr 1992; 120: 483–6
Kuppermann BD, Flores-Aguilar M, Quiceno JI, et al. Combination ganciclovir and foscarnet in the treatment of clinically resistant cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. Arch Ophthalmol 1993; 111: 1359–66
Dieterich DT, Poles MA, Lew EA, et al. Concurrent use of ganciclovir and foscarnet to treat cytomegalovirus infection in AIDS patients. J Infect Dis 1993; 167: 1184–8
Stoehr A, Plettenberg A, Wassmuth R, et al. Combination induction therapy for CMV- disease in AIDS- patients with half dose foscarnet and ganciclovir [abstract no. PO-B08-1258]. 9th International Conference on AIDS; 1993 Jun 6–11; Berlin, 345.
Flores-Aguilar M, Kuppermann BD, Quiceno JI, et al. Pathophysiology and treatment of clinically resistant cytomegalovirus retinitis. Ophthalmology 1993; 100: 1022–31
Salzberger B, Stoehr A, Heise W, et al. Foscarnet and ganciclovir combination therapy for severe CMV-disease in HIV-infected patients [abstract no. PO-B08-1344]. 9th International Conference on AIDS; 1993 Jun 6–11; Berlin, 359.
Peters M, Schürmann D, Bergmann F, et al. Safety of alternating ganciclovir and foscarnet maintenance therapy in human immunodeficiency virus (HlV)-related cytomegalovirus infections. An open-labeled pilot study. Scand J Infect Dis 1994; 26: 49–54
LeHoang P, Robinet M, Marcel P, et al. Comparative study of foscarnet and DHPG in the treatment of CMV retinitis in AIDS [abstract no. 90]. Invest Ophthalmol Vis Sci 1988; 29 Suppl.: 42
Moyle G, Harman C, Mitchell S, et al. Foscarnet and ganciclovir in the treatment of CMV retinitis in AIDS patients: a randomised comparison. J Infect 1992; 25: 21–7
Studies of Ocular Complications of AIDS (SOCA) Research Group. Mortality in patients with the Acquired Immune Deficiency Syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992; 326: 213–20
Lalezari JP. Oral vs intravenous ganciclovir (GCV) as maintenance treatment of newly diagnosed cytomegalovirus retinitis (CMVR) in AIDS [abstract]. Antiviral Res 1994; 23 Suppl.1: 45
Knospe V, Katlama C, Rozenbaum W, et al. A randomized controlled study of the efficacy and safety of maintenance treatment with IV & oral ganciclovir in the prevention of recurrence of cytomegalovirus retinitis in AIDS patients [abstract no. PO-B08-1257]. 9th International Conference on AIDS; 1993 Jun 6–11; Berlin, 345.
Squires KE, Stempien MJ, Shadman A, et al. Oral ganciclovir (POG) versus intravenous ganciclovir (IVG) maintenance therapy for cytomegalovirus (CMV) retinitis in patients with AIDS: preliminary results of a phase III study [abstract no. 549], Abstracts of the 1st National Conference on Human Retroviruses; 1993 Dec; Washington, 154.
Cochereau-Massin I, Ghallab GL, Zazoun L, et al. Intravitreal ganciclovir: a 3-year experience [abstract no. 023]. Conference Européenne sur les Aspects Cliniques et le Traitement de L’infection a VIH; 1992 Mar 12–13.
Cochereau-Massin I, Lehoang P, Lautier-Frau M, et al. Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology 1991; 98: 1348–55
Lieberman R, Orellana J. Intraocular ganciclovir in patients with persistent active cytomegalovirus retinitis. 9th International Conference on AIDS; 1993 Jun 6-11; Berlin, 423
Hodge W, Lalonde R, Deschenes J. The clinical course of CMV retinitis during maintenance therapy with intraocular ganciclovir [abstract]. Clin Infect Dis 1993; 17: 561
Orellana J, Lieberman RM, Peairs R, et al. Intravitreal therapy with ganciclovir for posterior pole cytomegalovirus retinitis in AIDS patients [letter]. Br J Ophthalmol 1990; 14: 511
Orduna DE, Olea JL, Mateos J, et al. Retinitis por citomagalovirus en pacientes con sida: aspectos clinicos y resultados del tratamiento con ganciclovir intravitreo. Arch Soc Esp Oftal 1990; 60: 713–20
Polsky B, Wolitz R, Cantrill H, et al. Intravitreal (IVL) ganciclovir (GCV) salvage therapy (Rx) for cytomegalovirus (CMV) retinitis (ACTG 085): a preliminary report [abstract no. W.B.2340]. Proceedings of the VII International Conference on AIDS; 1991 Jun 16–21; Florence, 267.
Díaz-Llopis M, José Martos M, Espana E, et al. Liposomally-entrapped ganciclovir for the treatment of cytomegalovirus retinitis in AIDS patients. Experimental toxicity and pharmacokinetics, and clinical trial. Documenta Opthalmologica 1992; 82: 297–305
Robinson M, Smith D, Betts R, et al. Ganciclovir implant for CMV retinitis treatment [abstract no. PO-B16-1726]. 9th International Conference on AIDS; 1993 Jun 6–11; Berlin, 423
Skolnik PR. Treatment of CMV retinitis [letter]. N Engl J Med 1992; 326: 1701
Harb GE, Bacchetti P, Jacobson MA. Survival of patients with AIDS and cytomegalovirus disease treated with ganciclovir or foscarnet. AIDS 1991; 5: 959–65
Bertoni G, Blini M, Perez A, et al. Survival of patients with AIDS after development of cytomegalovirus retinitis [abstract no. M.B.2387]. 7th International Conference on AIDS; Florence; 1991 Jun 16–21, 278.
Holland GN, Sison RF, Jatulis DE, et al. Survival of patients with the acquired immune deficiency syndrome after development of cytomegamovirus retinopathy. Ophthalmology 1990; 97: 204–11
Katlama C. Cytomegalovirus gastrointestinal disease in acquired immune deficiency syndrome. Eur J Gastroenterol Hepatol 1992; 4: 443–8
Dieterich DT, Rahmin M. Cytomegalovirus colitis in AIDS — presentation in 44 patients and a review of the literature. J Acquir Immune Defic Syndr 1991; 4 Suppl. 1: 29–35
Dieterich DT, Chachoua A, Lafleur F, et al. Ganciclovir treatment of gastrointestinal infections caused by cytomegalovirus in patients with AIDS. Rev Infect Dis 1988; 10: 532–7
Chachoua A, Dieterich DT, Krasinski K, et al. Ganciclovir in the treatment of cytomegalovirus gastrointestinal disease with the acquired immunodeficiency syndrome. Ann Intern Med 1987; 107: 133–7
Dieterich DT, Kotler DP, Busch DF, et al. Ganciclovir treatment of cytomegalovirus colitis in AIDS: a randomized, doubleblind, placebo-controlled multicenter study. J Infect Dis 1993; 167: 278–82
Heise W, Nehm K, Skörde J, et al. Ganciclovir in CMV gastrointestinal disease — a randomised double-blind study of two dose regimens in acute therapy [abstract no. PO-B19-1837]. 9th International Conference on Aids; 1993 Jun 6-11; Berlin, 441.
Stratta RJ. Clinical patterns and treatment of cytomegalovirus infection after solid-organ transplantation. Transplant Proc 1993; 25 Suppl.4: 15-21
Dunn DL, Najarian JS. New approaches to the diagnosis, prevention, and treatment of cytomegalovirus infection after transplantation. Am J Surg 1991; 161: 250–5
Farrugia E, Schwab TR. Management and prevention of cytomegalovirus infection after renal transplantation. Mayo Clin Proc 1992; 67: 879–90
Winston DJ, Ho WG, Bartoni K, et al. Ganciclovir therapy for cytomegalovirus infections in recipients of bone marrow transplants and other immunosuppressed patients. Rev Infect Dis 1988; 10: S547–53
Aulitzky WE, Tilg H, Niederwieser G, et al. Ganciclovir and hyperimmunoglobulin for treating cytomegalovirus infection in bone marrow transplant recipients. J Infect Dis 1988; 158: 488–9
Reed EC, Wolford JL, Kopecky PS, et al. Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients. A randomized, placebo-controlled trial. Ann Intern Med 1990; 112: 505–10
Reed EC, Dandliker PS, Meyers JD, et al. Treatment of cytomegalovirus pneumonia with 9-[2-hydroxyl-1-(hydroxymethyl) ethoxymethyl] guanine and high-dose corticosteroids. Ann Intern Med 1986; 105: 214–5
Bratanow NC, Ash RC, Turner PA, et al. Successful treatment of serious cytomegalovirus (CMV) disease with 9 (1,3-dihy-droxy-2-propoxymethyl) guanine (ganciclovir, DHPG) and intravenous immunoglobulin (IVIG) in bone marrow transplant (BMT) patients [abstract no. 253]. Exp Hematol 1987; 15: 541
Emanuel D, Cunningham I, Jules-Elysee K, et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med 1988; 109: 777–82
Reed EC, Bowden RA, Dandliker PS, et al. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med 1988; 109: 783–8
Schmidt GM, Kovacs A, Zaia JA, et al. Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients. Transplantation 1988; 46: 905–7
Verdonck LF, de Gast GC, Dekker AW, et al. Treatment of cytomegalovirus pneumonia after bone marrow transplantation with cytomegalovirus immunoglobulin combined with ganciclovir. Bone Marrow Transplant 1989; 4: 187–9
Winston DJ, Ho WG, Champlin RE. Ganciclovir and intravenous immunoglobulin in bone marrow transplants [abstract no. C 041]. J Cell Biochem 1990; 14: 270
Jordan ML, Hrebinko Jr RL, Dummer JS. Therapeutic use of ganciclovir for invasive cytomegalovirus infection in cadaveric renal allograft recipients. J Urol 1992; 148: 1388–92
Guerin C, Pozzetto B, Broyet C, et al. Ganciclovir therapy of symptomatic cytomegalovirus infection in renal transplant recipients. Nephrol Dial Transplant 1989; 4: 906–10
Buturovic-Ponikvar J, Kandus A, Malovrh M, et al. Ganciclovir treatment for cytomegalovirus infections in renal transplant recipients. Transplant Proc 1992; 24: 1921–3
De Koning J, van Dorp WT, van Es LA, et al. Ganciclovir effectively treats cytomegalovirus disease after solid-organ transplantation, even during rejection treatment. Nephrol Dial Transplant 1992; 7: 350–6
Nicholson ML, Veitch PS, Donnelly PK, et al. Treatment of renal transplant-associated cytomegalovirus infection with ganciclovir. Transplant Proc 1990; 22: 1811–2
Lumbreras C, Otero JR, Aguado JM, et al. Prospective study of infection by cytomegalovirus in liver transplant recipients. Med Clin 1992; 99: 401–5
Sanchez-Turriön V, Cuervas-Mons V, Portero F, et al. Prospective study of the incidence, timing, significance, risk factors and outcome of cytomegalovirus infection in transplant patients with double-drug immunosuppression and no prophylactic antiviral therapy. Transplant Proc 1993; 25: 1786
Cerrina J, Bavoux E, Le Roy Ladurie F, et al. Ganciclovir treatment of cytomegalovirus infection in heart-lung and doublelung transplant recipients. Transplant Proc 1991; 23: 1174–5
Cooper DKC, Novitzky D, Schlegel V, et al. Successful management of symptomatic cytomegalovirus disease with ganciclovir after heart transplantation. J Heart Lung Transplant 1991; 10: 656–63
Mullen GM, O’Keefe PJ, Heroux A, et al. Successful treatment of life-threatening cytomegalovirus infections with ganciclovir in cardiac transplant recipients. J Am Coll Cardiol 1990; 15 Suppl.A: 225
Van Son WJ, van den Berg AP, The TH, et al. Preemtive therapy with ganciclovir for early high-risk CMV infection allows effective treatment with antithymocyte globulin of steroid-resistant rejection after renal transplantation. Transplant Proc 1993; 25: 1436–8
Einsele H, Ehninger G, Steidle M, et al. Polymerase chain reaction to evaluate antiviral therapy for cytomegalovirus disease. Lancet 1991; 338: 1170–2
Bacigalupo A, Tedone E, Sanna MA, et al. CMV infections following allogeneic BMT: risk factors, early treatment and correlation with transplant related mortality. Haematologica 1992; 77: 507–13
Schwarz TF, Loeschke K, Hanus I, et al. CMV encephalitis during ganciclovir therapy of CMV retinitis. Infection 1990; 18: 289–90
Milpied N, Harousseau JL, Moreau P, et al. DHPG at CMV viremia after allogeneic bone marrow transplantation. Result over a four year period. Bone Marrow Transplant 1991; 7 (2 Suppl.): 46
Atkinson K, Downs K, Golenia M, et al. Prophylactic use of ganciclovir in allogeneic bone marrow transplantation -absence of clinical cytomegalovirus infection. Br J Haematol 1991; 79: 57–62
Yau JC, Dimopoulos MA, Huan SD, et al. Prophylaxis of cytomegalovirus infection with ganciclovir in allogenic marrow transplantation. Eur J Haematol 1991; 47: 371–6
Goodrich JM, Mori M, Gleaves CA, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991; 325: 1601–7
Schmidt GM, Horak DA, Niland JC, et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. N Engl J Med 1991; 324: 1005–11
Lehn P, Quessar A, Devergie A, et al. Treatment of severe cytomegalovirus infection with ganciclovir and high-dose intravenous immunoglobulin in patients with allogeneic bone marrow transplants. A pilot study. Nouv Rev Fr Hematol 1990; 32: 17–20
Singh N, Yu VL, Mieles L, et al. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomised trial. Ann Intern Med 1994; 120: 375–81
Levy MF, Crippin JS, Gonwa TA, et al. Cytomegalovirus (CMV) infections in liver transplant (Ltx) recipients: morbidity in the DHPG era [abstract no. 950]. Hepatology 1992; 16: 282A
Cohen AT, Ogrady JG, Sutherland S, et al. Controlled trial of prophylactic versus therapeutic use of ganciclovir after liver transplantation in adults. J Med Virol 1993; 40: 5–9
Stratta RJ, Shaeffer MS, Cushing KA, et al. A randomized prospective trial of acyclovir and immune globulin prophylaxis in liver transplant recipients receiving OKT3 therapy. Arch Surg 1992: 55-64
Singh N, Dummer JS, Khusne S, et al. Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies. J Infect Dis 1988: 124-31
Lumbreras C, Otero JR, Herrero JA, et al. Ganciclovir prophylaxis decreases frequency and severity of cytomegalovirus disease in seropositive liver transplant recipients treated with OKT3 monoclonal antibodies. Antimicrob Agents Chemother 1993; 37: 2490–2
Ladurie FL, Cerrina J, Bavoux E, et al. Ganciclovir for prevention of cytomegalovirus (CMV) infection in lung transplant (LT) recipients [abstract]. Chest 1991; 100: 62S
Duncan SR, Paradis IL, Dauber JH, et al. Ganciclovir prophylaxis for cytomegalovirus infections in pulmonary allograft recipients. Am Rev Respir Dis 1992; 146: 1213–5
Merigan TC, Renlund DG, Keay S, et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 1992; 326: 1182–6
Schmuth M, Grimm M, Wisser W, et al. Perioperative ganciclovir-prophylaxis after lung transplantation does not reduce incidence of CMV-infection [abstract]. Chest 1992; 102 Suppl.2: 181
Enright H, Haake R, Weisdorf D, et al. Cytomegalovirus pneumonia after bone marrow transplantation. Risk factors and response to therapy. Transplantation 1993; 55: 1339–46
Reusser P. Cytomegalovirus infection and disease after bone marrow transplantation: epidemiology, prevention, and treatment. Bone Marrow Transplant 1991; 7 Suppl. 3: 52–6
Goodrich JM, Bowden RA, Fisher L, et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993; 118: 173–8
Von Bueltzingsloewen A, Bordigoni P, Witz F, et al. Prophylactic use of ganciclovir for allogeneic bone marrow transplant recipients. Bone Marrow Transplant 1993; 12: 197–202
Winston DJ, Ho WG, Bartoni K, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med 1993; 118: 179–84
Rondeau E, Bourgeon B, Peraldi MN, et al. Effect of prophylactic ganciclovir on cytomegalovirus infection in renal transplant recipients. Nephrol Dial Transplant 1993; 8: 858–62
Green M, Reyes J, Nour B, et al. Randomized trial of ganciclovir followed by high-dose oral acyclovir vs ganciclovir alone in the prevention of cytomegalovirus disease in pediatric liver transplant recipients: preliminary analysis. Transplant Proc 1994; 26: 173–4
Megison SM, Andrews WS. Combination therapy with ganciclovir and intravenous IgG for cytomegalovirus infections in pediatric liver transplant recipients. Transplantation 1991; 52: 151–4
Prokurat S, Drabik E, Grenda R. Ganciclovir in cytomegalovirus prophylaxis in high-risk pediatric renal transplant recipients. Transplant Proc 1993; 25: 2577
Nigro G, Scholz H, Bartmann U. Ganciclovir therapy for symptomatic congenital cytomegalovirus infection in infants: a two regimen experience. J Pediatr 1994; 124: 318–22
Hocker JR, Cook LN, Adams G, et al. Ganciclovir therapy of congenital cytomegalovirus pneumonia. Pediatr Infect Dis J 1990; 9: 743–5
Evans DGR, Lyon AJ. Fatal congenital cytomegalovirus infection acquired by an intra-uterine transfusion. Eur J Pediatr 1991; 150: 780–1
Reigstad H, Bjerknes R, Markestad T, et al. Ganciclovir therapy of congenital cytomegalovirus disease. Acta Paediatr 1992; 81: 707–8
Attard-Montalto SP, English MC, Stimmler L, et al. Ganciclovir treatment of congenital cytomegalovirus infection: a report of two cases. Scand J Infect Dis 1993; 25: 385–8
Junker AK, Matheson D, Tingle AJ, et al. Immune responses after ganciclovir and immunoglobulin therapy of infants. Pediatr Infect Dis J 1991; 10: 256–8
Tricoire J, Rolland M, Régnier C. Ganciclovir therapy of congenital cytomegalovirus infection. Arch Fr Pediatr 1993; 50: 173
Fletcher CV. Treatment of herpesvirus infections in HIV-infected individuals. Ann Pharmacother 1992; 26: 955–62
DeArmond B. Safety considerations in the use of ganciclovir in immunocompromised patients. Transplant Proc 1991; 23 Suppl. 1: 26–9
Henderson JR. Use of ganciclovir in the treatment of cytomegalovirus infections. Br J Clin Pharmacol 1989; 43: 231–7
Snoeck R, Lagneaux L, Delforge A, et al. Inhibitory effects of potent inhibitors of human immunodeficiency virus and cytomegalovirus on the growth of human granulocyte-macrophage progenitor cells in vitro. Eur J Clin Microbiol Infect Dis 1990; 9: 615–9
Crosier PS, Clark SC. Basic biology of hematopoietic growth factors. Semin Oncol 1992; 19: 349–61
Jacobson MA, Stanley HD, Heard SE. Ganciclovir with recombinant methionyl human granulocyte colony-stimulating factor for treatment of cytomegalovirus disease in AIDS patients. AIDS 1992; 6: 515–7
Diflo T, Kou P, Lewis WD, et al. Simultaneous use of ganciclovir and granulocyte colony stimulating factor in liver transplant recipients [abstract no. 933]. Hepatology 1992: 278A
Hardy WD. Combined ganciclovir and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of cytomegalovirus retinitis in AIDS patients. J Acquir Immune Defic Syndr 1991; 4 Suppl. 1: 22–8
Chachoua A, Dieterich DT. 9-1,3 dihydroxy-2 propoxymethyl guanine in patients with AIDS and CMV infections [abstract]. Clin Res 1986; 34: 514a
Jabs DA, Newman C, De Bustros S, et al. Treatment of cytomegalovirus retinitis with ganciclovir. Ophthalmology 1987; 94: 824–30
Keay S, Bissett J, Merigon TC. Ganciclovir treatment of cytomegalovirus infections in iatrogenically immunocompromised patients. J Infect Dis 1987; 156: 1016–21
Keay S, Petersen E, Icenogle T, et al. Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients. Rev Infect Dis 1988; 10: S563–72
Orellana J, Teich SA, Friedman AH, et al. Combined short- and long-term therapy for the treatment of cytomegalovirus retinitis using ganciclovir (BW B759U). Ophthalmology 1987; 94: 831–8
Snydman DR. Ganciclovir therapy for cytomegalovirus disease associated with renal transplants. Rev Infect Dis 1988; 10: S554–62
Barton TL, Roush MK, Dever LL. Seizures associated with ganciclovir therapy. Pharmacotherapy 1992; 12: 413–5
Chen JL, Brocavich JM, Lin AYF. Psychiatric disturbances associated with ganciclovir therapy. Ann Pharmacother 1992; 26: 193–5
Baudouin C, Gastaud P. A modified procedure for intravitreal injections of ganciclovir in the treatment of cytomegalovirus retinitis. Ophthalmology 1992; 99: 1183
Chen S, Stroh EM, Wald K. Xanthomonas maltophilia endophthalmitis after implantation of sustained-release ganciclovir. Am J Ophthalmol 1992; 114: 772–3
Faulds D, Brogden RN. Didanosine: a review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection. Drugs 1992; 44: 94–116
Jacobson MA, Owen W, Campbell J. Tolerability of combined ganciclovir and didanosine for the treatment of cytomegalovirus disease associated with AIDS. Clin Infect Dis 1993; 16 Suppl. 1: 69–73
Syntex Laboratories Inc. Ganciclovir prescribing information,. Palo Alto, California, USA, 1992
Bachman DM. Treatment of CMV retinitis. N Engl J Med 1992; 326: 1702
Palestine AG, Polis MA, De Smet MD, et al. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med 1991; 115: 665–73
Author information
Authors and Affiliations
Additional information
Various sections of the manuscript reviewed by: A. Bacigalupo, Divisione di Ematologia II, Centro Trapianti di Midollo Osseo, Ospedale S. Martino, Genova, Italy; G.L. Buchshacher, McArdle Laboratory for Cancer Research, Department of Oncology, Medical School, University of Wisconsin, Madison, Wisconsin, USA; F Campos, Servei de Laboratori, Hospital de Sabadell, Parc Taulí, Barcelona, Spain; E. De Clercq, Rega Institute, Katholieke Universiteit Leuven, Leuven, Belgium; H. Einsele, Medizinische Klinik und Poliklinik, Eberhard-Karls-Universität, Tübingen, Germany; F. Fraunfelder, Casey Eye Institute, Portland, Oregon, USA; D.J. Jeffries, Department of Virology, Medical College of Saint Bartholomew’s Hospital, University of London, London, England; T. Naito, Department of Ophthalmology, Tokushima University School of Medicine, Tokushima, Japan; E.C. Reed, Section of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Rights and permissions
About this article
Cite this article
Markham, A., Faulds, D. Ganciclovir. Drugs 48, 455–484 (1994). https://doi.org/10.2165/00003495-199448030-00009
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199448030-00009